Repligen (NASDAQ:RGEN) Shares Gap Up – Here’s Why

Repligen Co. (NASDAQ:RGEN) shares gapped up before the market opened on Tuesday . The stock had previously closed at $168.01, but opened at $176.29. Repligen shares last traded at $172.44, with a volume of 272,942 shares traded.

Wall Street Analyst Weigh In

RGEN has been the topic of a number of research reports. HC Wainwright cut their target price on shares of Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Canaccord Genuity Group initiated coverage on Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Wolfe Research initiated coverage on Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Finally, Canaccord Genuity Group assumed coverage on shares of Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $184.73.

Repligen Stock Up 2.9 %

The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The firm’s 50-day moving average price is $150.83 and its 200 day moving average price is $146.40. The firm has a market cap of $9.69 billion, a P/E ratio of -467.41, a price-to-earnings-growth ratio of 4.51 and a beta of 0.97.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. Repligen’s quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.23 EPS. As a group, research analysts expect that Repligen Co. will post 1.54 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in RGEN. UMB Bank n.a. raised its stake in shares of Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after buying an additional 110 shares in the last quarter. First Turn Management LLC bought a new stake in Repligen in the third quarter worth about $13,202,000. Thrivent Financial for Lutherans lifted its holdings in Repligen by 6.1% in the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock valued at $95,037,000 after acquiring an additional 36,773 shares during the last quarter. Geneva Capital Management LLC boosted its position in shares of Repligen by 8.5% during the 3rd quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company’s stock valued at $20,638,000 after purchasing an additional 10,908 shares in the last quarter. Finally, TimesSquare Capital Management LLC grew its stake in shares of Repligen by 14.6% in the 3rd quarter. TimesSquare Capital Management LLC now owns 275,627 shares of the biotechnology company’s stock worth $41,019,000 after purchasing an additional 35,115 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.